| NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression J Wehkamp, J Harder, M Weichenthal, M Schwab, E Schäffeler, M Schlee, ... Gut 53 (11), 1658-1664, 2004 | 1147 | 2004 |
| Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease J Maul, C Loddenkemper, P Mundt, E Berg, T Giese, A Stallmach, M Zeitz, ... Gastroenterology 128 (7), 1868-1878, 2005 | 842 | 2005 |
| TGF-β and fibrosis in different organs—molecular pathway imprints D Pohlers, J Brenmoehl, I Löffler, CK Müller, C Leipner, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792 (8), 746-756, 2009 | 815 | 2009 |
| Effects of antibiotics on gut microbiota K Lange, M Buerger, A Stallmach, T Bruns Digestive Diseases 34 (3), 260-268, 2016 | 662 | 2016 |
| Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in … C Schmidt, T Giese, B Ludwig, I Mueller-Molaian, T Marth, S Zeuzem, ... Inflammatory bowel diseases 11 (1), 16-23, 2005 | 396 | 2005 |
| Multisystem inflammatory syndrome in children—initial therapy and outcomes MBF Son, N Murray, K Friedman, CC Young, MM Newhams, LR Feldstein, ... New England Journal of Medicine 385 (1), 23-34, 2021 | 395 | 2021 |
| Drug delivery strategies in the therapy of inflammatory bowel disease C Lautenschläger, C Schmidt, D Fischer, A Stallmach Advanced drug delivery reviews 71, 58-76, 2014 | 298 | 2014 |
| Adverse effects of biologics used for treating IBD A Stallmach, S Hagel, T Bruns Best practice & research Clinical gastroenterology 24 (2), 167-182, 2010 | 292 | 2010 |
| Nano-and microscaled particles for drug targeting to inflamed intestinal mucosa—A first in vivo study in human patients C Schmidt, C Lautenschlaeger, EM Collnot, M Schumann, C Bojarski, ... Journal of controlled release 165 (2), 139-145, 2013 | 265 | 2013 |
| Immunohistochemical and electron microscopic study of interaction of Yersinia enterocolitica serotype O8 with intestinal mucosa during experimental enteritis C Hanski, U Kutschka, HP Schmoranzer, M Naumann, A Stallmach, ... Infection and immunity 57 (3), 673-678, 1989 | 237 | 1989 |
| Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease A Stallmach, D Schuppan, HH Riese, H Matthes, EO Riecken Gastroenterology 102 (6), 1920-1929, 1992 | 226 | 1992 |
| European Crohn’s and Colitis Organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease G Doherty, KH Katsanos, J Burisch, M Allez, K Papamichael, A Stallmach, ... Journal of Crohn's and Colitis 12 (1), 17-31, 2018 | 212 | 2018 |
| Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study DC Baumgart, B Bokemeyer, A Drabik, A Stallmach, S Schreiber, ... Alimentary pharmacology & therapeutics 43 (10), 1090-1102, 2016 | 208 | 2016 |
| Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011 A Dignass, JC Preiß, DE Aust, F Autschbach, A Ballauff, G Barretton, ... Zeitschrift fur Gastroenterologie 49 (9), 1276-1341, 2011 | 195 | 2011 |
| Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. A Stallmach, B Von Lampe, H Matthes, G Bornhöft, EO Riecken Gut 33 (3), 342-346, 1992 | 194 | 1992 |
| Updated German clinical practice guideline on" Diagnosis and treatment of Crohn's disease" 2014 JC Preiss, B Bokemeyer, HJ Buhr, A Dignaß, W Häuser, F Hartmann, ... Zeitschrift fur Gastroenterologie 52 (12), 1431-1484, 2014 | 190 | 2014 |
| Rapid mucosal CD4+ T-cell depletion and enteropathy in simian immunodeficiency virus–infected rhesus macaques S Kewenig, T Schneider, K Hohloch, K Lampe–Dreyer, R Ullrich, N Stolte, ... Gastroenterology 116 (5), 1115-1123, 1999 | 183 | 1999 |
| Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease–a prospective multicenter observational study A Stallmach, C Langbein, R Atreya, T Bruns, A Dignass, K Ende, J Hampe, ... Alimentary pharmacology & therapeutics 44 (11-12), 1199-1212, 2016 | 182 | 2016 |
| S1-Leitlinie post-COVID/long-COVID AR Koczulla, T Ankermann, U Behrends, P Berlit, S Böing, F Brinkmann, ... Pneumologie 75 (11), 869-900, 2021 | 180 | 2021 |
| Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals J Dietz, S Susser, J Vermehren, KH Peiffer, G Grammatikos, A Berger, ... Gastroenterology 154 (4), 976-988. e4, 2018 | 179 | 2018 |